Inhaled Pulmonary Vasodilators in the Neonatal and Pediatric ICU

Area of Science:

• Pediatric critical care medicine
• Neonatal pharmacology
• Respiratory system therapeutics

Background:

• Inhaled pulmonary vasodilators are crucial for pediatric pulmonary hypertension.
• Inhaled nitric oxide (INO) is FDA-approved for neonates >34 weeks gestational age with persistent pulmonary hypertension.
• Off-label use of other inhaled vasodilators is prevalent in neonates and children, lacking robust evidence.

Purpose of the Study:

• To review current evidence on inhaled vasodilators for pediatric pulmonary hypertension.
• To evaluate inhaled nitric oxide (INO) delivery devices.
• To explore alternative inhaled vasoactive agents due to INO cost and off-label use concerns.

Main Methods:

• Literature review of existing studies on inhaled vasodilators in neonatal and pediatric intensive care.
• Analysis of evidence supporting the efficacy and safety of inhaled pulmonary vasodilators.
• Evaluation of technological advancements in inhaled nitric oxide generation devices.

Main Results:

• Limited FDA-approved inhaled vasodilators exist for pediatric pulmonary hypertension, with INO being the primary option.
• Significant use of off-label inhaled vasodilators occurs despite insufficient supporting evidence.
• New tankless nitric oxide generation devices are emerging, potentially impacting treatment accessibility and cost.

Conclusions:

• Evidence-based use of inhaled vasodilators is critical in pediatric critical care.
• Further research is needed to support the efficacy and safety of alternative inhaled vasodilators.
• Technological innovations in INO delivery may offer new therapeutic avenues for neonatal and pediatric pulmonary hypertension.